Significant stride in the fight against malaria.
Medicines for Malaria Venture (MMV) today revealed that Brazil has become the first malaria-endemic country to approve the use of single-dose tafenoquine (Kozenis) for children aged two years and above in combination with chloroquine.
Kozenis was developed by UK pharma major GSK (LSE: GSK) in partnership with MMV, a not-for-profit consortium, and was also approved by Australia’s Therapeutic Goods Administration (TGA) last year. Tafenoquine was also approved by the US Food and Drug Administration under the Krintafel trade name in July 2018, making it then the first new treatment for P. vivax malaria in over 60 years.
This approval by Anvisa, the National Regulatory Agency for Brazil, is a remarkable achievement that promises to revolutionize the landscape of malaria treatment and prevention, MMV noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze